Theraclion's Sales Multiplied by 5 in The First Half of 2021
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo:
ALTHE, PEA-PME eligible), an innovative healthtech company with its
leading edge high-tech echotherapy platform, today announces
its sales revenues for the first half of 2021.
Theraclion on its way to recover pre Covid
After several months of lockdown and suspension of non-urgent
medical treatments due to the global health crisis, Theraclion’s
commercial activity has resumed. Intensified efforts have been
dedicated to the sales of systems and services. As a result, 4
systems (including 3 second hand) were sold against 0 in 2020 and
services have increased by 25%. In the first half of
2021,Theraclion SA achieved a turnover of € 885 K a fivefold
increase on 2020 on its way to recover the level of activities in
the pre Covid period.
Half year revenue/K€
Sales of systems
Sales of consumables
Sales of services
Total sales Theraclion SA
Out of which Thyroid and
Out of which Varicose Veins
Getting ready for a successful second semester with a solid
Theraclion is now reaching a new level of technological maturity
with the development of SONOVEIN S®. This new system allow doctors
to treat at least twice as fast the patients for the non-invasive
treatment of varicose veins. On ECHOPULSE® platform, a phase 2
investigation is underway in partnership with the cancer centre of
University of Virginia (United States) for patients with stage 1, 2
& 3 invasive breast cancer using the combination with
immuno-therapy an chemio-therapy.
Vascular physicians have shown interest in SONOVEIN S®, the last
generation of SONOVEIN®. Theraclion is now aiming at the opening of
new treatment sites in Europe and Asia and is making progress in
the submission of SONOVEIN® to the Food and Drug Administration
(FDA) in the United States.
Theraclion has recently announced a reinforced Board of
Directors. On the back of the strong potential of Theraclion,
Bernard Sabrier and Unigestion acting on their own behalf, have
increased their position and own now more than 20% of the company.
The reinforced governance has lead to a strong strategy for the
development of the company.
Theraclion has developed an extensive research plan to further
advance conventional treatments approaches, enhance surgical
protocols and improve clinical outcomes. Its evolving platform is
creating an environment without scalpels, scars and stress.
Theraclion is an innovative healthtech company which is evolving
therapeutic interventions with extracorporeal solutions enabling to
mitigate perioperative structures and reducing patient burden. Its
leading edge high-tech echotherapy platform is currently approved
in the treatment of non-invasive ablation of breast fibroadenomas
and thyroid nodules with ECHOPULSE®. Additionally, SONOVEIN® is the
only non-invasive ablation therapy for varicose veins, allowing
treatment without catheters, chemical injections, incisions, nor
This advanced ablation platform couples high-intensity focused
ultrasound, detailed ultrasound medical imaging, and advanced data
learning. For practitioners, this provides high-level handling
precision, unsurpassed ease of use, intelligent AI guidance and
opens continuous learning capability earlier treatment
opportunities otherwise delayed and world wide replicability.
Located in Greater Paris, Theraclion has over half of its
25-strong team dedicated to R&D and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
version on businesswire.com: https://www.businesswire.com/news/home/20210712005613/en/
David Auregan Chief Finance Officer
Anja Kleber VP Marketing, Market Access & Sales Francophonia
Historical Stock Chart
From Apr 2022 to May 2022
Historical Stock Chart
From May 2021 to May 2022